These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1666104)

  • 1. Antibody response of kittens after vaccination followed by exposure to feline leukemia virus-infected cats.
    Hawks DM; Legendre AM; Rohrbach BW; Sebring R; Chavez L; Chu HJ; Acree WM
    J Am Vet Med Assoc; 1991 Nov; 199(10):1463-9. PubMed ID: 1666104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure.
    Legendre AM; Hawks DM; Sebring R; Rohrbach B; Chavez L; Chu HJ; Acree WM
    J Am Vet Med Assoc; 1991 Nov; 199(10):1456-62. PubMed ID: 1666103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
    Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
    J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of three commercial feline leukemia virus vaccines against methylprednisolone acetate-augmented oronasal challenge exposure with virulent virus.
    Pedersen NC; Johnson L
    J Am Vet Med Assoc; 1991 Nov; 199(10):1453-5. PubMed ID: 1666102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
    Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
    J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection.
    Hines DL; Cutting JA; Dietrich DL; Walsh JA
    J Am Vet Med Assoc; 1991 Nov; 199(10):1428-30. PubMed ID: 1666097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of feline leukemia virus immunity.
    Charreyre C; Pedersen NC
    J Am Vet Med Assoc; 1991 Nov; 199(10):1316-24. PubMed ID: 1666074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a whole killed feline leukemia virus vaccine.
    York SM; York CJ
    J Am Vet Med Assoc; 1991 Nov; 199(10):1419-22. PubMed ID: 1666095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a genetically engineered vaccine against feline leukemia virus infection.
    Kensil CR; Barrett C; Kushner N; Beltz G; Storey J; Patel U; Recchia J; Aubert A; Marciani D
    J Am Vet Med Assoc; 1991 Nov; 199(10):1423-7. PubMed ID: 1666096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection.
    Clark N; Kushner NN; Barrett CB; Kensil CR; Salsbury D; Cotter S
    J Am Vet Med Assoc; 1991 Nov; 199(10):1433-43. PubMed ID: 1666099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
    Grosenbaugh DA; Leard T; Pardo MC
    J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
    Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
    J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Year two of follow-up evaluation of a randomized, blind field trial of a commercial feline leukemia virus vaccine.
    Scarlett JM; Pollock RV
    J Am Vet Med Assoc; 1991 Nov; 199(10):1431-2. PubMed ID: 1666098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feline leukemia virus vaccine development.
    Sebring RW; Chu HJ; Chavez LG; Sandblom DS; Hustead DR; Dale B; Wolf D; Acree WM
    J Am Vet Med Assoc; 1991 Nov; 199(10):1413-9. PubMed ID: 1666094
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
    Grosenbaugh DA; Leard T; Pardo MC; Motes-Kreimeyer L; Royston M
    Vet Ther; 2004; 5(4):258-62. PubMed ID: 15719325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a killed, whole virion feline leukemia virus vaccine.
    Tizard I; Bass EP
    J Am Vet Med Assoc; 1991 Nov; 199(10):1410-3. PubMed ID: 1666093
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine.
    Jirjis FF; Davis T; Lane J; Carritt K; Sweeney D; Williams J; Wasmoen T
    Vet Ther; 2010; 11(2):E1-6. PubMed ID: 20957616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of humoral immunity tests in FeLV infected cats.
    Charreyre CE; Pedersen N
    Dev Biol Stand; 1990; 72():197-200. PubMed ID: 2178116
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy studies of live- and killed-feline leukemia virus vaccines.
    Pedersen NC; Theilen GH; Werner LL
    Am J Vet Res; 1979 Aug; 40(8):1120-6. PubMed ID: 230767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of cats against progressive fibrosarcomas and persistent leukemia virus infection by vaccination with feline leukemia cells.
    Grant CK; de Noronha F; Tusch C; Michalek MT; McLane MF
    J Natl Cancer Inst; 1980 Dec; 65(6):1285-92. PubMed ID: 6253714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.